EIP
TEVA icon

Epoch Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Epoch Investment Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-179,540
Closed -$3.16M – 317
2017
Q3 		$3.16M Sell
179,540
-1,771,403
-91% -$39.9M 0.01% 264
2017
Q2 		$64.8M Buy
1,950,943
+64,822
+3% +$2.01M 0.22% 109
2017
Q1 		$60.5M Buy
1,886,121
+260,295
+16% +$8.88M 0.2% 114
2016
Q4 		$58.9M Sell
1,625,826
-1,829,396
-53% -$73M 0.22% 99
2016
Q3 		$159M Sell
3,455,222
-789,725
-19% -$41.2M 0.59% 62
2016
Q2 		$213M Buy
4,244,947
+212,090
+5% +$11.3M 0.8% 47
2016
Q1 		$216M Sell
4,032,857
-392,257
-9% -$23M 0.82% 44
2015
Q4 		$290M Buy
4,425,114
+1,525,374
+53% +$94.3M 1.15% 28
2015
Q3 		$164M Buy
+2,899,740
New +$188M 0.64% 57
2015
Q2 		– Sell
-220,755
Closed -$13.8M – 277
2015
Q1 		$13.8M Buy
+220,755
New +$12.8M 0.05% 183

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Epoch Investment Partners's TEVA Position: Q4 2017 in Review

Epoch Investment Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 179,540 shares — an estimated $3.16M sold.

Epoch Investment Partners first reported a position in TEVA in Q1 2015 and held it in 10 quarters. The position peaked at $290M in Q4 2015. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Epoch Investment Partners reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Epoch Investment Partners sold 179,540 Teva Pharmaceuticals shares in Q4 2017, an estimated $3.16M.
  • Epoch Investment Partners first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 10 quarters.
  • Epoch Investment Partners's Teva Pharmaceuticals position peaked at $290M in Q4 2015.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Epoch Investment Partners's 13F filing for Q4 2017, filed 13 Feb 2018.